Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: An independent cancer biomarker

Clinical Chemistry

Volumn 55, Issue 5, 2009, Pages 904-913

  Korbakis, Dimitrios ^a   Gregorakis, Alkiviades K ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN 5;

ARTICLE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 65949111299     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.103788     Document Type: Article

References (40)

1. Chokkalingam AP, Stanczyk FZ, Reichardt JK, Hsing AW. Molecular epidemiology of prostate cancer: hormone-related genetic loci. Front Biosci 2007;12:3436-3460
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004; 41:265-312. (Pubitemid 38888061)
4. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005;224:1-22. (Pubitemid 40720363)
5. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology 2000;55:694-699
6. Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros D, et al. High sensitive immunoenzymatic detection of insulin-like growth factor 1 (IGF-1), human glandular kallikrein 2 (hK2) and total prostate specific antigen (PSA) for discriminating between prostate cancer and benign prostatic hyperplasia. Prostate 2003;54: 220-229
7. Magklara A, Scorilas A, Catalona WJ, Diamandis EP. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 1999; 45:1960-1966. (Pubitemid 29522004)
8. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, et al. Quantitative analysis of kallikrein 15 gene expression in prostatic tissue. J Urol 2003;169:361-364
9. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, Diamandis EP. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 2003;63:6543-6546 (Pubitemid 37255209)
10. Yousef GM, Scorilas A, Jung K, Aschworth L, Diamandis EP. The new human kallikrein gene KLK15 is up-regulated in prostate cancer. J Biol Chem 2001;276:53-61.
11. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79. (Pubitemid 46427999)
12. Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem 2006;387:665-675 (Pubitemid 43964788)
13. Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein locus on chromosome 19q13.3-q13.4. Biochem Biophys Res Co 2000;276:125-133
14. Yousef GM, Diamandis EP. The new kallikrein-like gene, KLK-L2: molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem 1999;274:37511-37516 (Pubitemid 30026803)
15. Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem 1999;274: 30033-30040 (Pubitemid 29483386)
16. Emami N, Diamandis EP. Human tissue kallikreins: a road under construction. Clin Chim Acta 2007;381:78-84. (Pubitemid 46719134)
17. Vaisanen V, Lovgren J, Hellman J, Piironen T, Lilja H, Pettersson K. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis 1999;2:91-97 (Pubitemid 29259939)
18. Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005; 124:198-203. (Pubitemid 40100969)
19. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J Invest Dermatol 2006;126:2338-2342
20. Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem 2005;386:1173-1184
21. Shinoda Y, Kozaki K, Imoto I, Obara W, Tsuda H, Mizutani Y, et al. Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells. Cancer Sci 2007 Jul;98:1078-1086
22. Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003;9:1710-1720 (Pubitemid 36554595)
23. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001;84: 643-650
24. Luo LY, Yousef G, Diamandis EP. Human tissue kallikreins and testicular cancer. APMIS 2003; 111:225-32; discussion 32-33 (Pubitemid 36566692)
25. Yousef GM, Polymeris ME, Grass L, Soosaipillai A, Chan PC, Scorilas A, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-3965
26. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, Diamandis EP. Downregulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 2002;51:126-132
27. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzone R, et al. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin Chem 2002;48:1241-1250
28. Planque C, de Monte M, Guyetant S, Rollin J, Desmazes C, Panel V, et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun 2005;329:1260-1266
29. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
30. Magklara A, Scorilas A, Stephan C, Kristiansen G, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) in malignant vs non-malignant prostatic tissue. Urology 2000;56:527-532 (Pubitemid 30658202)
31. Nakamura T, Stephan C, Scorilas A, Yousef GM, Jung K, Diamandis EP. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology 2003;61:1042-1046 (Pubitemid 36547767)
32. Stavropoulou P, Gregorakis AK, Plebani M, Scorilas A. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer. Clin Chim Acta 2005;357:190-195 (Pubitemid 40884600)
33. Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, Diamandis EP. Human Kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favorable prognosis in breast cancer. Br J Cancer 2002;86:1457-1464 (Pubitemid 34548070)
34. Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 2004;22:678-685 (Pubitemid 41095071)
35. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001; 7:806-811
36. Borgono CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, et al. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res 2006;12:1487-1493
37. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003;63:2771-2774
38. Vizoso F, Sánchez LM, Díez-Itza I, Merino AM, López-Otín C. Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol 1995;13:54-61.
39. Scorilas A, Diamandis EP, Levesque MA, Papanistasiou-Diamandi A, Khosravi MJ, Giai M, et al. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in nodepositive patients. Clin Cancer Res 1999;5:1778-1785
40. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008;107: 309-330